Intrommune Therapeutics's Product Videos
Intrommune Therapeutics's Products & Differentiation
See Intrommune Therapeutics's products and how their products differentiate from alternatives and competitors
Oral Mucosal Immunotherapy to desensitize people with peanut allergy from having severe allergic reactions. INT301 utilizes a specially formulated toothpaste that optimizes exposure of allergenic proteins to a patients immune system, while cleaning their teeth
Subscribe to see more
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
When was Intrommune Therapeutics founded?
Intrommune Therapeutics was founded in 2015.
Where is Intrommune Therapeutics's headquarters?
Intrommune Therapeutics's headquarters is located at 20 W 125th St., New York.
What is Intrommune Therapeutics's latest funding round?
Intrommune Therapeutics's latest funding round is Series B.
How much did Intrommune Therapeutics raise?
Intrommune Therapeutics raised a total of $220K.
Who are the investors of Intrommune Therapeutics?
Investors of Intrommune Therapeutics include Red Bear Angels and Netcapital.
Who are Intrommune Therapeutics's competitors?
Competitors of Intrommune Therapeutics include DBV Technologies and 1 more.
What products does Intrommune Therapeutics offer?
Intrommune Therapeutics's products include INT301 and 1 more.
You May Also Like
Moonlight Therapeutics develops a targeted therapy that reduces the potential for a severe anaphylactic reaction from accidental exposure.
Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergies. The company’s lead program, ADP101, is being advanced as a broad-spectrum oral immunotherapy treatment to mitigate food allergies triggered by single or multiple proteins from an expansive set of common allergens. Alladapt Immunotherapeutics was founded in 2018 and is based in Menlo Park, California.
DBV Technologies (NASDAQ: DBVT) is a global, clinical-stage biopharmaceutical company aiming to advance epicutaneous immunotherapy. It is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this class of non-invasive product candidates, the company is dedicated to safely transforming the care of food-allergic patients. DBV Technologies was founded in 2002 and is based in Montrouge, France.
Aimmune Therapeutics develops treatments for food allergies using standardized, pharmaceutical-grade food allergens and characterized oral desensitization immunotherapy, or CODIT, system. The CODIT system is built on a foundation of extensive independent scientific research on oral immunotherapy that shows that most patients with food allergies can become desensitized to the food by ingesting their allergens in gradually increasing amounts and then maintaining a steady daily dose thereafter. Aimmune aims to offer standardized product, protocol and support services to protect people with food allergies from accidental exposures by achieving clinically meaningful levels of desensitization to food allergens.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.